

AMEDISYS INC  
Form 10-Q  
November 01, 2011  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington D.C. 20549

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2011

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from            to

Commission File Number: 0-24260

**AMEDISYS, INC.**

(Exact Name of Registrant as Specified in its Charter)

Edgar Filing: AMEDISYS INC - Form 10-Q

**Delaware** **11-3131700**  
(State or other jurisdiction of **(I.R.S. Employer**  
  
**incorporation or organization)** **Identification No.)**  
**5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816**  
  
(Address of principal executive offices, including zip code)  
  
(225) 292-2031 or (800) 467-2662  
  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer   
Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company   
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date, is as follows: Common stock, \$0.001 par value, 29,435,988 shares outstanding as of October 27, 2011.

**Table of Contents**

**TABLE OF CONTENTS**

<u>SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION</u>	1
<u>PART I. FINANCIAL INFORMATION</u>	
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED):	
<u>CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2011 AND DECEMBER 31, 2010</u>	2
<u>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2011 AND 2010</u>	3
<u>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2011 AND 2010</u>	4
<u>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</u>	5
ITEM 2. <u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	16
ITEM 3. <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	29
ITEM 4. <u>CONTROLS AND PROCEDURES</u>	29
<u>PART II. OTHER INFORMATION</u>	
ITEM 1. <u>LEGAL PROCEEDINGS</u>	30
ITEM 1A. <u>RISK FACTORS</u>	30
ITEM 2. <u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	31
ITEM 3. <u>DEFAULTS UPON SENIOR SECURITIES</u>	31
ITEM 4. <u>RESERVED</u>	31
ITEM 5. <u>OTHER INFORMATION</u>	31
ITEM 6. <u>EXHIBITS</u>	32
<u>SIGNATURES</u>	34
<u>INDEX TO EXHIBITS</u>	35

---

**Table of Contents**

**SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION**

**Special Caution Concerning Forward-Looking Statements**

*When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission ( SEC ), or in statements made by or on behalf of our company, words like believes, belief, expects, plans, anticipates, intends, projects, estimates, may, might, would, should and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, adverse effects of a failure of the Federal government to fund government programs in which we participate, such as Medicare or Medicaid, adverse effects of a possible delay in the Federal budget process or a Federal government shutdown, our ability to open agencies, acquire additional agencies and integrate and operate these agencies effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies (including in the estimate of our preliminary impairment charge), our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, changes in or developments with respect to any litigation or investigations relating to the Company, including the United States Senate Committee on Finance inquiry, the SEC investigation and the U.S. Department of Justice Civil Investigative Demand and various other matters, many of which are beyond our control.*

*Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December 31, 2010, filed with the SEC on February 22, 2011, particularly Part I, Item 1A. Risk Factors therein, which are incorporated herein by reference and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.*

**Available Information**

*Our company website address is [www.amedisys.com](http://www.amedisys.com). We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled Investors on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link SEC filings ) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link Corporate Governance ).*

*Additionally, our filings can be obtained at the SEC's Public Reference Room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at (800) SEC-0330. Our electronically filed reports can also be obtained on the SEC's internet site at <http://www.sec.gov>.*

**Table of Contents****PART I. FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****AMEDISYS, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS**

(Amounts in thousands, except share data)

(Unaudited)

	September 30, 2011	December 31, 2010
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 29,462	\$ 120,295
Patient accounts receivable, net of allowance for doubtful accounts of \$18,110 and \$20,977	151,208	141,549
Prepaid expenses	10,950	9,947
Other current assets	13,795	22,259
<b>Total current assets</b>	<b>205,415</b>	<b>294,050</b>
Property and equipment, net of accumulated depreciation of \$85,351 and \$78,074	146,928	138,554
Goodwill	335,811	791,412
Intangible assets, net of accumulated amortization of \$19,875 and \$17,135	52,259	53,393
Deferred tax asset	77,173	
Other assets, net	29,190	22,454
<b>Total assets</b>	<b>\$ 846,776</b>	<b>\$ 1,299,863</b>
<b>LIABILITIES AND EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 22,347	\$ 20,663
Payroll and employee benefits	77,038	82,961
Accrued expenses	67,939	61,254
Current portion of long-term obligations	33,525	37,178
Current portion of deferred income taxes	8,659	14,285
<b>Total current liabilities</b>	<b>209,508</b>	<b>216,341</b>
Long-term obligations, less current portion	119,726	144,688
Deferred income taxes		52,286
Other long-term obligations	5,561	6,833
<b>Total liabilities</b>	<b>334,795</b>	<b>420,148</b>
Commitments and Contingencies - Note 6		
Equity:		
Preferred stock, \$0.001 par value, 5,000,000 shares authorized; none issued or outstanding		
Common stock, \$0.001 par value, 60,000,000 shares authorized; 30,717,775 and 29,867,701 shares issued; and 30,029,731 and 29,232,807 shares outstanding	30	29
Additional paid-in capital	428,400	407,156
Treasury stock at cost, 688,044 and 634,894 shares of common stock	(15,762)	(14,022)
Accumulated other comprehensive income	15	25

## Edgar Filing: AMEDISYS INC - Form 10-Q

Retained earnings	97,891	484,669
Total Amedisys, Inc. stockholders' equity	510,574	877,857
Noncontrolling interests	1,407	1,858
Total equity	511,981	879,715
Total liabilities and equity	\$ 846,776	\$ 1,299,863

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents****AMEDISYS, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(Amounts in thousands, except per share data)

(Unaudited)

	For the Three-Month Periods Ended September 30,		For the Nine-Month Periods Ended September 30,	
	2011	2010	2011	2010
Net service revenue	\$ 374,861	\$ 404,680	\$ 1,112,885	\$ 1,239,996
Cost of service, excluding depreciation and amortization	205,657	206,302	589,983	619,654
General and administrative expenses:				
Salaries and benefits	87,106	89,712	253,618	265,266
Non-cash compensation	3,150	2,636	8,265	8,317
Other	47,697	54,852	139,906	152,297
Provision for doubtful accounts	4,628	5,261	9,918	14,069
Depreciation and amortization	9,826	8,832	28,907	25,297
Goodwill and other intangibles impairment charge	574,114		574,114	
Operating expenses	932,178	367,595	1,604,711	1,084,900
Operating (loss) income	(557,317)	37,085	(491,826)	155,096
Other (expense) income:				
Interest income	18	197	225	374
Interest expense	(2,187)	(2,277)	(6,693)	(7,038)
Equity in earnings from unconsolidated joint ventures	325	788	1,114	2,310
Miscellaneous, net	(176)	(42)	(940)	(1,585)
Total other expense, net	(2,020)	(1,334)	(6,294)	(5,939)
(Loss) income before income taxes	(559,337)	35,751	(498,120)	149,157
Income tax benefit (expense)	135,640	(13,943)	111,458	(58,153)
Net (loss) income	(423,697)	21,808	(386,662)	91,004
Net (income) attributable to noncontrolling interests	(25)	(174)	(116)	(522)
Net (loss) income attributable to Amedisys, Inc.	\$ (423,722)	\$ 21,634	\$ (386,778)	\$ 90,482
Net (loss) income per share attributable to Amedisys, Inc. common stockholders:				
Basic	\$ (14.73)	\$ 0.77	\$ (13.53)	\$ 3.23
Diluted	\$ (14.73)	\$ 0.76	\$ (13.53)	\$ 3.18
Weighted average shares outstanding:				
Basic	28,770	28,096	28,587	28,007
Diluted	28,770	28,499	28,587	28,490

The accompanying notes are an integral part of these condensed consolidated financial statements.





**Table of Contents****AMEDISYS, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(Amounts in thousands)

(Unaudited)

	<b>For the Nine-Month Periods Ended September 30,</b>	
	<b>2011</b>	<b>2010</b>
<b>Cash Flows from Operating Activities:</b>		
Net (loss) income	\$ (386,662)	\$ 91,004
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	28,907	25,297
Provision for doubtful accounts	9,918	14,069
Non-cash compensation	8,265	8,317
401(k) employer match	5,845	17,536
Loss on disposal of property and equipment	1,796	2,314
Deferred income taxes	(133,623)	300
Equity in earnings of unconsolidated joint ventures	(1,114)	(2,310)
Amortization of deferred debt issuance costs	1,182	1,182
Return on equity investment	1,088	1,390
Goodwill and other intangibles impairment charge	574,114	
Changes in operating assets and liabilities, net of impact of acquisitions:		
Patient accounts receivable	(5,883)	(250)
Other current assets	8,960	16,251
Other assets	(4,304)	(2,181)
Accounts payable	814	3,195
Accrued expenses	(1,475)	(4,057)
Other long-term obligations	(3,535)	551
<b>Net cash provided by operating activities</b>	<b>104,293</b>	<b>172,608</b>
<b>Cash Flows from Investing Activities:</b>		
Proceeds from sale of deferred compensation plan assets	859	2,425
Purchases of deferred compensation plan assets	(472)	(1,053)
Purchases of property and equipment	(38,573)	(37,535)
Purchase of investment	(4,500)	
Acquisitions of businesses, net of cash acquired	(125,977)	(3,121)
Acquisitions of reacquired franchise rights		(2,376)
<b>Net cash used in investing activities</b>	<b>(168,663)</b>	<b>(41,660)</b>
<b>Cash Flows from Financing Activities:</b>		
Proceeds from issuance of stock upon exercise of stock options and warrants	245	1,494
Proceeds from issuance of stock to employee stock purchase plan	3,961	4,690
Tax benefit from stock option exercises	(427)	2,427
Non-controlling interest distribution	(568)	(185)
Purchase of company stock		(11,796)
Principal payments of long-term obligations	(29,674)	(34,026)
<b>Net cash used in financing activities</b>	<b>(26,463)</b>	<b>(37,396)</b>

Edgar Filing: AMEDISYS INC - Form 10-Q

Net (decrease) increase in cash and cash equivalents	(90,833)	93,552
Cash and cash equivalents at beginning of period	120,295	34,485
Cash and cash equivalents at end of period	\$ 29,462	\$ 128,037
<b>Supplemental Disclosures of Cash Flow Information:</b>		
Cash paid for interest	\$ 7,094	\$ 7,949
Cash paid for income taxes, net of refunds received	\$ 11,273	\$ 49,870
<b>Supplemental Disclosures of Non-Cash Financing and Investing Activities:</b>		
Notes payable issued for/assumed in acquisitions	\$ 1,058	\$ 750
Notes payable issued for software licenses	\$	\$ 10,801

The accompanying notes are an integral part of these condensed consolidated financial statements.

---

**Table of Contents**

**AMEDISYS, INC. AND SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS**

Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries ( Amedisys, we, us, or our ) are a multi-state provider of home health and hospice services with approximately 85% of our revenue derived from Medicare for the three-month periods ended September 30, 2011 and 2010, and approximately 85% and 86% of our revenue derived from Medicare for the nine-month periods ended September 30, 2011 and 2010, respectively. As of September 30, 2011, we had 482 Medicare-certified home health and 90 Medicare-certified hospice agencies in 45 states within the United States, the District of Columbia and Puerto Rico.

***Basis of Presentation***

In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles ( U.S. GAAP ). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission ( SEC ) on February 22, 2011 (the Form 10-K ), which includes information and disclosures not included herein.

***Use of Estimates***

Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

***Reclassifications and Comparability***

Certain reclassifications have been made to prior periods financial statements in order to conform them to the current period s presentation.

***Principles of Consolidation***

These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.

***Equity Investments***

We consolidate subsidiaries and/or joint ventures when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.

For subsidiaries or joint ventures in which we do not have a controlling interest or for which we are not the primary beneficiary, we record such investments under the equity method of accounting.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Revenue Recognition***

We earn net service revenue through our home health and hospice agencies by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day episode of care as episodic-based revenue.

**Table of Contents**

When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results.

*Home Health Revenue Recognition***Medicare Revenue**

Net service revenue is recorded under the Medicare prospective payment system ( PPS ) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment ( LUPA ) if the number of visits was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required (thresholds set at 6, 14 and 20 visits); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare Program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

In addition to the items noted above, the Centers for Medicare and Medicaid Services ( CMS ) recently added two new provisions to PPS which was implemented April 1, 2011: (1) a face-to-face encounter requirement and (2) changes to the therapy assessment schedule, which require additional patient evaluations and certifications. As a condition for Medicare payment, the first new provision mandates that prior to certifying a patient's eligibility for the home health benefit, the certifying physician must document that he or she, or an allowed non-physician practitioner, has had a face-to-face encounter with the patient. The encounter must occur in the timeframe of 90 days prior to the start of care or 30 days after the start of care. Documentation regarding these encounters must be present on certifications. Under the second new provision, CMS imposed therapy assessment requirements. An assessment by a professional qualified therapist must take place at least once every 30 days during a therapy patient's course of treatment. For those qualified patients that require greater than 13 or 19 therapy visits, a qualified therapist must perform the therapy service required, assess the patient, and measure and document effectiveness of additional visit. This requirement applies to each therapy discipline caring for the patient, but the assessment must be performed close to, but no later than, the 13<sup>th</sup> and 19<sup>th</sup> visits. Management evaluates the potential for revenue adjustments as a result of these regulations and, when appropriate, provides allowances for losses based upon the best available information.

We make adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. In addition, management evaluates the potential for revenue adjustments and, when appropriate, provides allowances for losses based upon the best available information. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of September 30, 2011 and 2010, the difference between the cash received from Medicare for a request for anticipated payment ( RAP ) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding patient accounts receivable in our condensed consolidated balance sheets for such periods.

**Non-Medicare Revenue**

*Episodic-based Revenue.* We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

*Non-episodic Based Revenue.* Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross



---

## **Table of Contents**

revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.

### *Hospice Revenue Recognition*

#### **Hospice Medicare Revenue**

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four main levels of care we provide are routine care, general inpatient care, continuous home care and respite care. Routine care accounts for 96% and 97% of our total net Medicare hospice service revenue for the three and nine-month periods ended September 30, 2011, respectively, as compared to 97% for the three and nine-month periods ended September 30, 2010, respectively. We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable.

Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if a cap has been exceeded. We record these adjustments as a reduction to revenue and an increase in other accrued liabilities. We have settled our Medicare hospice reimbursements for all fiscal years through October 31, 2009. For the cap years ended October 31, 2010 and October 31, 2011, we have \$4.0 million recorded for estimated amounts due back to Medicare in other accrued liabilities as of September 30, 2011 and \$1.9 million recorded as of December 31, 2010. As a result of our adjustments, we believe our revenue and patients accounts receivable are recorded at amounts that will be ultimately realized.

Effective April 1, 2011, CMS implemented its hospice regulation requiring that a hospice physician or nurse practitioner have a face-to-face encounter with hospice patients during the 30 day period prior to the 180th-day recertification (third benefit period) and each subsequent recertification, to gather clinical findings to determine continued eligibility for hospice care, and that the certifying hospice physician or nurse practitioner attest that such a visit took place. Management evaluates the potential for revenue adjustments due to these regulations and when appropriate provides allowances for losses based upon the best available information.

#### **Hospice Non-Medicare Revenue**

We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per visit rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receivable.

### ***Patient Accounts Receivable***

Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. There is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables, and thus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at 360 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible.

We believe the credit risk associated with our Medicare accounts, which represent 74% and 76% of our net patient accounts receivable at September 30, 2011 and December 31, 2010, respectively, is limited due to (i) our historical collection rate of over 99% from Medicare and (ii) the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. During the three and nine-month periods ended September 30, 2011, we recorded \$3.3 million and \$8.2 million, respectively, in estimated revenue adjustments to Medicare revenue as compared to \$2.7 million and \$4.4 million during the three and nine-month periods ended September 30, 2010, respectively.

We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.





---

## **Table of Contents**

### *Medicare Home Health*

For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed ( final billed ). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted.

### *Medicare Hospice*

For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient.

### *Non-Medicare Home Health and Hospice*

For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. We estimate an allowance for doubtful accounts to reduce the carrying amount of the receivables to the amounts we estimate will be ultimately collected. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. In addition, the amount of the allowance for doubtful accounts is based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectibility based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk.

### *Goodwill and Other Intangible Assets*

Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include but are not limited to, a significant adverse change in the business environment; regulatory environment or legal factors; or a substantial decline in market capitalization of our stock. To determine whether goodwill is impaired, we perform a two-step impairment test. In the first step of the test, the fair values of the reporting units are compared to their aggregate carrying values, including goodwill. If the fair value of the reporting unit is greater than its carrying amount, goodwill is not impaired and no further testing is required. If the fair value of the reporting unit is less than its carrying amount, we would proceed to step two of the test. In step two of the test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the fair value calculated in step one to all of the assets and liabilities of that reporting unit (including any recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value was reflective of the price paid to acquire the reporting unit. The implied fair value of goodwill is the excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit's assets and liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the goodwill at the analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that variance.

We calculate the estimated fair value of our reporting units using discounted cash flows as well as a market approach that compares our reporting units' earnings and revenue multiples to those of comparable public companies. To determine fair value we must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations in particular expected organic growth rates, future Medicare reimbursement rates, capital requirements and income taxes), long-term growth rates for determining terminal value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to, among other things, economic conditions, changes to our business model or changes in operating performance. These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. Significant differences between these estimates and actual cash flows could result in additional impairment in future periods.

## Edgar Filing: AMEDISYS INC - Form 10-Q

We completed our last annual impairment test of goodwill as of October 31, 2010 and determined that no goodwill impairment existed as of October 31, 2010. During the third quarter of 2011, indicators of potential impairment caused us to conduct an interim impairment test for goodwill and other intangible assets for our home health reporting unit. See Note 4 Goodwill and Other Intangible Assets, Net for additional information regarding our interim impairment test.

Intangible assets consist of Certificates of Need, licenses, acquired names, non-compete agreements and reacquired franchise rights. We amortize non-compete agreements, acquired names that we do not intend to use in the future and reacquired franchise rights on a straight-line basis over their estimated useful lives, which is generally three years for non-compete agreements and up to five years for reacquired franchise rights and acquired names.

### *Fair Value of Financial Instruments*

The following details our financial instruments where the carrying value and fair value differ (amounts in millions):

Financial Instrument	Fair Value at Reporting Date Using			
	As of September 30, 2011	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Long-term obligations	\$153.2	\$	\$158.1	\$

The estimates of the fair value of our long-term obligations are based upon a discounted present value analysis of future cash flows. Due to the existing uncertainty in the capital and credit markets, the actual rates that would be obtained to borrow under similar conditions could materially differ from the estimates we have used.

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:

Level 1 Quoted prices in active markets for identical assets and liabilities.

Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable and accrued expenses, we estimate the carrying amounts approximate fair value due to their short term maturity. Our deferred compensation plan assets are recorded at fair value.

**Table of Contents****Income Taxes**

We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date.

We recorded a tax benefit of \$139.5 million related to the \$574.1 million estimated goodwill and other intangibles impairment charge recorded in the current quarter. The difference between the benefit recorded and the statutory rate of 35% is due to allocating the impairment of goodwill between deductible and non-deductible goodwill for tax purposes.

Management regularly assesses the ability to realize deferred tax assets recorded in the Company's entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. During the three-month period ended September 30, 2011, we released a valuation allowance on specific deferred tax assets after we had undertaken tax planning which will allow for the utilization of state net operating losses which may have otherwise expired. As a result, the income tax provision and the net loss attributable to Amedisys, Inc. for the third quarter of 2011 included a one-time favorable impact of \$1.9 million. In the event future taxable income is below management's estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.

**Weighted-Average Shares Outstanding**

Net (loss) income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net (loss) income per share attributable to Amedisys, Inc. common stockholders and the shares which were anti-dilutive to the computation (amounts in thousands):

	For the Three-Month Periods Ended September 30,		For the Nine-Month Periods Ended September 30,	
	2011	2010	2011	2010
Weighted average number of shares outstanding basic	28,770	28,096	28,587	28,007
Effect of dilutive securities:				
Stock options		79		143
Non-vested stock and stock units		324		340
Weighted average number of shares outstanding diluted	28,770	28,499	28,587	28,490
Anti-dilutive securities	925	162	544	70

**Recently Issued Accounting Pronouncements**

In June 2011, the FASB issued Accounting Standards Update (ASU) 2011-05, *Comprehensive Income (Topic 220): Presentation of Comprehensive Income* requiring entities to present net income and other comprehensive income in either a single continuous statement or in two separate, but consecutive, statements of net income and other comprehensive income. The option to present items of other comprehensive income in the statement of changes in equity is eliminated. The ASU is effective for fiscal years and interim periods within those years, beginning after December 15, 2011, with early adoption permitted. We do not expect the adoption of this ASU to have a material impact on our consolidated financial statements.

In July 2011, the FASB ratified the final Emerging Issues Task Force Consensus on Issue No. 09-H, *Health Care Entities: Presentation and Disclosure of Net Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts*. The Consensus will require health care entities to separately present bad debt expense related to patient service revenue as a reduction to patient service revenue (net of contractual allowances and discounts). Health care entities will be required to disclose qualitative and quantitative information about the activity in the allowance for doubtful accounts, and their policies for assessing collectability in determining the timing and amount of revenue and bad debt expense. The Consensus will be effective for fiscal years and interim periods within those years beginning after December 15, 2011, with early application permitted. Retrospective application will be required for presenting bad debt expense related to patient service revenue as a reduction of revenue.

## Edgar Filing: AMEDISYS INC - Form 10-Q

The expanded disclosures are required to be applied prospectively. We expect the adoption of this final Consensus to decrease our net service revenue by the amount of the provision for doubtful accounts recorded, which will decrease gross margin; however, it will have no effect on net income.

In September 2011, the FASB issued ASU 2011-08, *Intangibles - Goodwill and Other (Topic 350)* allowing an entity the option to first perform a qualitative assessment to determine whether it is necessary to perform the traditional two-step goodwill impairment test to identify potential goodwill impairment and measure the amount of impairment loss to be recognized (if any). If, after performing the qualitative assessment, an entity concludes that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then no further impairment testing is necessary. The qualitative assessment includes assessing relevant events and circumstances such as macroeconomic conditions, industry and market conditions, cost factors, overall financial performance, relevant entity-specific events, events affecting a reporting unit or a sustained decrease in share price. The ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted.

### 3. ACQUISITIONS

We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health and hospice services. The purchase price paid for acquisitions is negotiated through arm's length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows for each transaction. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy.

#### *2011 Acquisitions*

On June 7, 2011, we acquired Beacon Hospice, Inc. ( Beacon ) for a total purchase price of \$126.0 million, net of cash acquired (subject to certain adjustments), of which \$8.2 million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of the transaction. Beacon owns and operates 22 hospice agencies and one inpatient unit servicing the states of Massachusetts, Maine, New Hampshire, Rhode Island and Connecticut. In

**Table of Contents**

connection with the acquisition, we recorded substantially the entire purchase price as goodwill (\$109.4 million), other intangibles (\$10.9 million) and other assets and liabilities, net (\$5.7 million).

The following table contains pro forma condensed consolidated statement of operations information assuming that the Beacon transaction closed on January 1, 2010, for the nine-month periods ended September 30, 2011 and 2010 (amounts in millions, except per share data):

	2011	2010
Net service revenue	\$ 1,146.5	\$ 1,295.5
Operating income	(489.2)	160.5
Net income	(386.1)	92.8
Basic earnings per share	\$ (13.51)	\$ 3.31
Diluted earnings per share	\$ (13.51)	\$ 3.26

Beacon's revenue and net income included in our condensed consolidated statement of operations from the acquisition date through September 30, 2011 is \$27.3 million and \$6.7 million, respectively.

**4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET**

As of September 30, 2011 and prior to our October 31 annual impairment test, we concluded that impairment indicators existed based upon our decline in market capitalization, third quarter results and recent forecasts which required us to perform an interim impairment test. As a result, we performed step one of the goodwill impairment test as prescribed by Accounting Standard Codification (ASC) Topic 350 Intangibles Goodwill and Other, which indicated that the fair value of the home health reporting unit was less than the book value of its net assets and the fair value of the hospice reporting unit was greater than the book value of its net assets. Therefore, the required second step of the assessment for the home health reporting unit was performed, in which the implied fair value of the home health reporting unit's goodwill was compared to the book value of that goodwill. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination, that is, the estimated fair value of the reporting unit is allocated to all of those assets and liabilities of that unit (including both recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the estimated fair value of the reporting unit was the purchase price paid. If the carrying amount of the reporting unit's goodwill is greater than the implied fair value of that reporting unit's goodwill, an impairment loss is recognized in the amount of the excess and is charged to operations. We determined the fair value of the reporting unit using discounted estimated future cash flows as well as a market approach that compared the home health reporting unit's earnings and revenue multiples to those of comparable public companies. We were required to allocate a significant portion of fair value to unrecorded intangible assets such as the Amedisys trade name and Medicare and CON licenses, but were not permitted to record these assets on our balance sheet.

As a result of our interim impairment assessment, we recognized an estimated non-cash goodwill impairment charge of \$565.0 million as of September 30, 2011. In addition, at this interim date and prior to our annual goodwill testing, we also reviewed the carrying value of the other identifiable intangible assets to determine whether they were impaired. As a result of the preliminary assessment, we recorded an additional estimated \$9.1 million non-cash other intangibles impairment charge as of September 30, 2011, due to a change in the fair values of various licenses, which are not being amortized, associated with certain prior year acquisitions. A deferred tax benefit of \$139.5 million was recognized as of September 30, 2011 as a result of the total amount of estimated impairment charges. The impairments primarily results from lower forecasted revenues as a result of recent reimbursement cuts, operating margins and declining growth rates from our home health reporting unit. These impairments did not have any impact on our compliance with our debt covenants or on our cash flows. Due to the complexity of the process, we will not fully complete the measurement of the implied fair value of goodwill under the second step of the test until the fourth quarter of 2011 and, accordingly, the goodwill and other intangible impairment charge included in our condensed consolidated statement of operations for the three and nine-months ended September 30, 2011 represents an estimate. Any adjustments to these amounts, which could be material, resulting from the completion of the measurement of the impairment charges will be recognized during the fourth quarter of 2011.

The fair value valuation of our home health reporting unit's assets and liabilities in the second step of the assessment fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our most recent forecasts and other estimates.

The following table summarizes the activity related to our goodwill and our other intangible assets, net, as of and for the nine-month period ended September 30, 2011 (amounts in millions):

Edgar Filing: AMEDISYS INC - Form 10-Q

	Home Health	Goodwill Hospice	Total
Balances at December 31, 2010	\$ 723.3	\$ 68.1	\$ 791.4
Additions		109.4	109.4
Impairment	(565.0)		(565.0)
Adjustments related to acquisitions			
Balances at September 30, 2011	\$ 158.3	\$ 177.5	\$ 335.8

	Certificates of Need and Licenses	Other Intangible Assets, Net Acquired Names of Business (1)	Non-Compete Agreements & Reacquired Franchise Rights (2)	Total
Balances at December 31, 2010	\$ 41.7	\$ 4.7	\$ 7.0	\$ 53.4
Additions	2.5	8.1	0.3	10.9
Write-off	(0.2)			(0.2)
Impairment	(9.1)			(9.1)
Amortization		(0.1)	(2.6)	(2.7)
Balances at September 30, 2011	\$ 34.9	\$ 12.7	\$ 4.7	\$ 52.3

- (1) Acquired Names of Business includes \$12.5 million of unamortized acquired names and \$0.2 million of amortized acquired names which have a weighted-average amortization period of 2.1 years.
- (2) The weighted-average amortization period of our non-compete agreements and reacquired franchise rights is 2.1 and 1.8 years, respectively.

#### 5. Long-Term Obligations

Long-term obligations, including capital lease obligations, consisted of the following for the periods indicated (amounts in millions):

**Table of Contents**

	September 30, 2011	December 31, 2010
<b>Senior Notes:</b>		
\$35.0 million Series A Notes; semi-annual interest only payments; interest rate at 6.07% per annum; due March 25, 2013	\$ 35.0	\$ 35.0
\$30.0 million Series B Notes; semi-annual interest only payments; interest rate at 6.28% per annum; due March 25, 2014	30.0	30.0
\$35.0 million Series C Notes; semi-annual interest only payments; interest rate at 6.49% per annum; due March 25, 2015	35.0	35.0
\$150.0 million Term Loan; \$7.5 million principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (0.99% at September 30, 2011); due March 26, 2013	45.0	67.5
Promissory notes	8.2	14.4
	153.2	181.9
Current portion of long-term obligations	(33.5)	(37.2)
<b>Total</b>	<b>\$ 119.7</b>	<b>\$ 144.7</b>

**Revolving Credit Facility**

On May 26, 2011, we entered into a First Amendment to our \$250.0 Million Revolving Credit Facility (the *First Amendment*). Under the terms of the First Amendment, (i) the financial covenant baskets relating to permitted *Investments in Joint Ventures* and other *Investments* were increased to give the Company greater flexibility, (ii) there was a non-substantive, clarifying amendment to the definition of *Permitted Acquisition* and (iii) certain other agreements, obligations and representations and warranties of the parties thereto were amended, modified and/or supplemented. In connection with the execution of the First Amendment, each existing guarantor under the Credit Agreement consented to the terms of the First Amendment.

Our weighted-average interest rate for our five year Term Loan for the three and nine-month periods ended September 30, 2011 was 1.0% as compared to 1.1% for the three and nine-month periods ended September 30, 2010.

As of September 30, 2011, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.9 and our fixed charge coverage ratio was 1.7.

As of September 30, 2011, our availability under our \$250.0 million Revolving Credit Facility was \$231.3 million as we had \$18.7 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

**6. COMMITMENTS AND CONTINGENCIES****Legal Proceedings**

In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows. We are also involved in the legal actions set forth below.

**United States Senate Committee on Finance Inquiry**

On May 12, 2010, we received a letter of inquiry from the United States Senate Committee on Finance (the *Committee*) requesting documents and information relating to our policies and practices regarding home therapy visits and therapy utilization trends. A similar letter was sent to the other major publicly traded home health care companies. We cooperated with the Committee with respect to this inquiry.

## Edgar Filing: AMEDISYS INC - Form 10-Q

On October 3, 2011, the Committee publicly issued a report titled *Staff Report on Home Health and the Medicare Therapy Threshold*. The Committee recommended that the CMS must move toward taking therapy out of the payment model. We believe that the issuance of the report concludes the Committee's inquiry, but are not in a position to speculate on the potential for future legislative or oversight action by the Committee.

### *Securities Class Action Lawsuits*

On June 7, 2010, a putative securities class action complaint was filed in the United States District Court for the Middle District of Louisiana against the Company and certain of our current and former senior executives. Additional putative securities class actions were filed in the United States District Court for the Middle District of Louisiana on July 14, July 16, and July 28, 2010.

On October 22, 2010, the Court issued an order consolidating the putative securities class action lawsuits and the Federal Derivative Actions (described immediately below) for pre-trial purposes. In the same order, the Court appointed the Public Employees Retirement System of Mississippi and the Puerto Rico Teachers' Retirement System as co-lead plaintiffs (together, the *Co-Lead Plaintiffs*) for the



---

## **Table of Contents**

putative class. On December 10, 2010, the Court also consolidated the ERISA class action lawsuit (described below) with the putative securities class actions and Federal Derivative Actions for pre-trial purposes.

On January 18, 2011, the Co-Lead Plaintiffs filed an amended, consolidated class action complaint (the *Securities Complaint*) which supersedes the earlier-filed securities class action complaints. The *Securities Complaint* alleges that the defendants made false and/or misleading statements and failed to disclose material facts about our business, financial condition, operations and prospects, particularly relating to our policies and practices regarding home therapy visits under the Medicare home health prospective payment system and the related alleged impact on our business, financial condition, operations and prospects. The *Securities Complaint* seeks a determination that the action may be maintained as a class action on behalf of all persons who purchased the Company's securities between August 2, 2005 and September 28, 2010 and an unspecified amount of damages. All defendants have moved to dismiss the *Securities Complaint*.

### *Derivative Actions*

On July 2, 2010, an alleged shareholder of the Company filed a derivative lawsuit in the United States District Court for the Middle District of Louisiana, purporting to assert claims on behalf of the Company against certain of our current and former officers and directors. Three similar derivative suits were filed in the United States District Court for the Middle District of Louisiana on July 15, July 21, and August 2, 2010 (together, the *Federal Derivative Actions*). We are named as a nominal defendant in all of those actions. As noted above, on October 22, 2010, the United States District Court for the Middle District of Louisiana issued an order consolidating the *Federal Derivative Actions* with the putative securities class action lawsuits and for pre-trial purposes.

On January 18, 2011, the plaintiffs in the *Federal Derivative Actions* filed a consolidated, amended complaint (the *Derivative Complaint*) which supersedes the earlier-filed derivative complaints. The *Derivative Complaint* alleges that certain of our current and former officers and directors breached their fiduciary duties to the Company by making allegedly false statements, by allegedly failing to establish sufficient internal controls over certain of our home health and Medicare billing practices, by engaging in alleged insider trading, and by committing unspecified acts of waste of corporate assets and unjust enrichment. All defendants in the *Federal Derivative Actions*, including the Company as a nominal defendant, have moved to dismiss the *Derivative Complaint*.

On July 23, 2010, a derivative suit was filed in the Nineteenth Judicial District Court, Parish of East Baton Rouge, State of Louisiana. That action also purports to assert claims on behalf of the Company against certain of our current and former officers and directors. On December 8, 2010, the Court entered an order staying the action in deference to the earlier-filed derivative actions pending in federal court.

### *ERISA Class Action Lawsuit*

On September 27, 2010 and October 22, 2010, separate putative class action complaints were filed in the United States District Court for the Middle District of Louisiana against us, certain of our current and former senior executives and members of our 401(k) Plan Administrative Committee. The suits allege violations of the Employee Retirement Income Security Act (*ERISA*) since January 1, 2006 and July 1, 2007, respectively. The plaintiffs brought the complaints on behalf of themselves and a class of similarly situated participants in our 401(k) plan. The plaintiffs assert that the defendants breached their fiduciary duties to the 401(k) Plan's participants by causing the 401(k) plan to offer and hold Amedisys common stock during the respective class periods when it was an allegedly unduly risky and imprudent retirement investment because of our alleged improper business practices. The complaints seek a determination that the actions may be maintained as a class action, an award of unspecified monetary damages and other unspecified relief. As noted above, on December 10, 2010, the Court consolidated the putative ERISA class actions with the putative securities class actions and derivative actions for pre-trial purposes. In addition, on December 10, 2010, the Court appointed interim lead counsel and interim liaison counsel in the ERISA class action.

On March 10, 2011, Wanda Corbin, Pia Galimba and Linda Trammell (the *Co-ERISA Plaintiffs*), filed an amended, consolidated class action complaint (the *ERISA Complaint*), which supersedes the earlier-filed ERISA class action complaints. The *ERISA Complaint* seeks a determination that the action may be maintained as a class action on behalf of themselves and a class of similarly situated participants in our 401(k) plan from January 1, 2008 through present. All of the defendants have moved to dismiss the *ERISA Complaint*.

### *SEC Investigation*

On June 30, 2010, we received notice of a formal investigation from the SEC and received a subpoena for documents relating to the matters under review by the United States Senate Committee on Finance and other matters involving our operations. We are cooperating with the SEC with respect to this investigation.



---

## **Table of Contents**

### *U.S. Department of Justice Civil Investigative Demand ( CID )*

On September 27, 2010, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act. The CID requires the delivery of a wide range of documents and information to the United States Attorney's Office for the Northern District of Alabama, relating to the Company's clinical and business operations, including reimbursement and billing claims submitted to Medicare for home health services, and related compliance activities. The CID generally covers the period from January 1, 2003. On April 26, 2011, we received a second CID related to the CID issued in September 2010, which generally covers the same time period as the previous CID and requires the production of additional documents. Subsequently, the Company and certain current and former employees have received CIDs for testimony. We are cooperating with the Department of Justice with respect to this investigation, and the requests for testimony.

We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the SEC investigation, the U.S. Department of Justice CIDs and the securities, shareholder derivative and ERISA litigation described above given the preliminary stage of these matters. The Company intends to continue to vigorously defend itself in the securities, shareholder derivative and ERISA litigation matters. No assurances can be given as to the timing or outcome of the SEC investigation, the U.S. Department of Justice CIDs or the securities, shareholder derivative and ERISA litigation matters described above or the impact of any of the inquiry, investigation or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows. In addition, while we believe the United States Senate Committee on Finance has completed its inquiry, we are not in a position to speculate on the potential for future legislative or oversight action by the Committee.

We recognize that additional putative securities class action complaints and other litigation could be filed, and that other investigations and actions could be commenced, relating to matters involving our home therapy visits and therapy utilization trends or other matters.

### *Third Party Audits*

We are subject in the ordinary course of our business from time to time to audits under various governmental programs in which third party firms engaged by CMS conduct extensive review of claims data to identify potential improper payments under the Medicare program.

In January 2010, our subsidiary that provides home health services in Dayton, Ohio received from a Medicare Program Safeguard Contractor ( PSC ) a request for records regarding 137 claims submitted by the subsidiary paid from January 2, 2008 through November 10, 2009 (the Claim Period ) to determine whether the underlying services met pertinent Medicare payment requirements. Based on the PSC's findings, which were extrapolated to all claims for home health services provided by the Dayton subsidiary paid during the Claim Period, on March 9, 2011, the Medicare Administrative Contractor for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately \$5.6 million. We dispute these findings and intend to vigorously seek to have these findings overturned, but no assurances can be given as to the timing or outcome of any appeal. As of September 30, 2011, we have recorded no liability for this claim.

In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor ( ZPIC ) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the Review Period ) to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations. Based on the ZPIC's findings, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the Medicare Administrative Contractor for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately \$5.5 million. We dispute these findings and intend to vigorously seek to have these findings overturned, but no assurances can be given as to the timing or outcome of any appeal. In the event we pay any amount of this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009. As of September 30, 2011, we have recorded no liability for this claim.

### *Insurance*

We are obligated for certain costs associated with our insurance programs, including employee health, workers' compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported, up to specified deductible limits. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.

Our health insurance has a retention limit of \$750.0 thousand, our workers' compensation insurance has a retention limit of \$350.0 thousand and our professional liability insurance has a retention limit of \$250.0 thousand.



**Table of Contents****Investments**

In June 2011, we purchased a limited partnership interest for \$2.0 million in a private investment fund. The purpose of the fund is to identify, fund and develop innovative solutions that have the potential to improve quality, reduce cost, and increase efficiency across a continuum of care for healthcare delivery systems. In addition, we have committed an additional \$18.0 million capital contribution to the fund on an as needed basis.

**7. SEGMENT INFORMATION**

Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the home of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. The other column in the following tables consists of costs relating to corporate support functions that are not directly attributable to a specific segment.

Management evaluates performance and allocates resources based on the operating income of the reportable segments, which exclude corporate expenses, but includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company's chief operating decision maker and therefore are not disclosed below. The following table summarizes our segment information for the periods indicated (amounts in millions):

	For the Three-Month Period Ended September 30, 2011			
	Home Health	Hospice	Other	Total
Net service revenue	\$ 310.4	\$ 64.5	\$	\$ 374.9
Cost of service, excluding depreciation and amortization	170.7	35.0		205.7
General and administrative expenses	74.5	12.5	51.0	138.0
Provision for doubtful accounts	4.0	0.6		4.6
Depreciation and amortization	3.7	0.2	5.9	9.8
Goodwill and other intangibles impairment charge	574.1			574.1
Operating expenses	827.0	48.3	56.9	932.2
Operating income (loss)	\$ (516.6)	\$ 16.2	\$ (56.9)	\$ (557.3)

	For the Three-Month Period Ended September 30, 2010			
	Home Health	Hospice	Other	Total
Net service revenue	\$ 368.5	\$ 36.2	\$	\$ 404.7
Cost of service, excluding depreciation and amortization	186.2	20.1		206.3
General and administrative expenses	92.0	9.4	45.8	147.2
Provision for doubtful accounts	5.1	0.2		5.3
Depreciation and amortization	3.8	0.2	4.8	8.8
Operating expenses	287.1	29.9	50.6	367.6
Operating income (loss)	\$ 81.4	\$ 6.3	\$ (50.6)	\$ 37.1

**Table of Contents**

	<b>For the Nine-Month Period Ended September 30, 2011</b>			
	<b>Home Health</b>	<b>Hospice</b>	<b>Other</b>	<b>Total</b>
Net service revenue	\$ 962.3	\$ 150.6	\$	\$ 1,112.9
Cost of service, excluding depreciation and amortization	509.1	80.9		590.0
General and administrative expenses	224.7	30.3	146.8	401.8
Provision for doubtful accounts	9.4	0.5		9.9
Depreciation and amortization	10.7	0.5	17.7	28.9
Goodwill and other intangibles impairment charge	574.1			574.1
<b>Operating expenses</b>	<b>1,328.0</b>	<b>112.2</b>	<b>164.5</b>	<b>1,604.7</b>
Operating income (loss)	\$ (365.7)	\$ 38.4	\$ (164.5)	\$ (491.8)
	<b>For the Nine-Month Period Ended September 30, 2010</b>			
	<b>Home Health</b>	<b>Hospice</b>	<b>Other</b>	<b>Total</b>
Net service revenue	\$ 1,137.0	\$ 103.0	\$	\$ 1,240.0
Cost of service, excluding depreciation and amortization	563.9	55.8		619.7
General and administrative expenses	269.4	25.1	131.3	425.8
Provision for doubtful accounts	12.9	1.2		14.1
Depreciation and amortization	11.3	0.4	13.6	25.3
<b>Operating expenses</b>	<b>857.5</b>	<b>82.5</b>	<b>144.9</b>	<b>1,084.9</b>
Operating income (loss)	\$ 279.5	\$ 20.5	\$ (144.9)	\$ 155.1

**Table of Contents****ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and nine-month periods ended September 30, 2011. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission (SEC) on February 22, 2011 (the Form 10-K), which are incorporated herein by this reference.

Unless otherwise provided, Amedisys, we, us, our and the Company refer to Amedisys, Inc. and our consolidated subsidiaries.

**Overview**

We are a leading provider of high-quality, low-cost home health services to the chronic, co-morbid, aging American population with approximately 85% of our revenue was derived from Medicare for the three-month periods ended September 30, 2011 and 2010, respectively and approximately 85% and 86% of our revenue was derived from Medicare for the nine-month periods ended September 30, 2011 and 2010, respectively. During the three-month period ended September 30, 2011, we had \$374.9 million in net service revenue, net loss per diluted share of \$14.73 and cash flow from operations of \$27.8 million. During the third quarter of 2011, we recorded a \$574.1 million estimated impairment charge of goodwill and other intangibles as a result of the decline in our market capitalization and forecasts during the quarter see Goodwill Impairment below for additional information. For the nine-month period ended September 30, 2011, we had \$1.1 billion in net service revenue, net loss per diluted share of \$13.53 and cash flow from operations of \$104.3 million.

Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. As of September 30, 2011, we had 482 Medicare-certified home health and 90 Medicare-certified hospice agencies in 45 states within the United States, the District of Columbia and Puerto Rico as detailed below:

	Owned and Operated Agencies	
	Home Health	Hospice
At December 31, 2010	486	67
Acquisitions		22
Start-ups	7	3
Closed/Consolidated	(11)	(2)
At September 30, 2011	482	90

As part of our ongoing management of our portfolio of agencies, we began a review of our agencies' operating performance during the third quarter of 2011. Our review considered the current financial performance, market penetration, forecasted market growth, and the impact of the proposed 2012 CMS payment revision. Subsequent to September 30, 2011, we have identified approximately 50 agencies which we plan to exit during the fourth quarter. These agencies will be included in discontinued operations in the period in which the final determination has been made which is expected to be in the fourth quarter of 2011. The financial performance of the agencies currently identified is as follows:

	Number of Agencies	For the Three-Month Period Ended September 30, 2011		For the Nine-Month Period Ended September 30, 2011	
		Net Service Revenue	Operating loss	Net Service Revenue	Operating loss
Closures	32	\$ 4.6	\$ (2.2)	\$ 14.2	\$ (6.3)
Consolidations/Unopened Startups	18	3.8	(0.4)	11.9	(0.5)
Total	50	\$ 8.4	\$ (2.6)	\$ 26.1	\$ (6.8)

## Edgar Filing: AMEDISYS INC - Form 10-Q

When we refer to same store business, we mean home health and hospice agencies that we have operated for at least the last twelve months; when we refer to acquisitions, we mean home health and hospice agencies that we acquired within the last twelve months; and when we refer to start-ups, we mean any home health or hospice agency opened by us in the last twelve months. Once an agency has been in operation for a twelve month period, the results for that particular agency are included as part of our same store business from that date forward. When we refer to episodic-based revenue, admissions, recertifications or completed episodes, we



---

## **Table of Contents**

mean home health revenue, admissions, recertifications or completed episodes of care for those payors that pay on an episodic-basis, which includes Medicare and other insurance carriers including Medicare Advantage programs.

### **Goodwill Impairment**

As of September 30, 2011, we concluded that impairment indicators existed based on our decline in market capitalization, third quarter results and recent forecasts which prompted us to perform an interim impairment test. As a result of our preliminary assessment we recorded an estimated non-cash goodwill and other intangible assets impairment charge of \$574.1 million. Due to the complexity of the process, we will not fully complete the measurement of the implied fair value of goodwill until the fourth quarter of 2011 and, accordingly, the goodwill impairment charge included in our condensed consolidated statement of operations for the three and nine-months ended September 30, 2011 represents an estimate. Any adjustments to these amounts, which could be material, resulting from the completion of the measurement of the impairment charges will be recognized during the fourth quarter of 2011. In addition, a further significant and sustained decline in our stock price and market capitalization, a significant decline in our expected future cash flows, a significant adverse change in the business climate or slower growth rates could result in the need to perform an impairment analysis under Accounting Standard Codification ( ASC ) Topic 350 Intangibles Goodwill and Other in future periods. See Note 4 Goodwill and Other Intangibles Assets, Net to our condensed consolidated financial statements for additional information on the impairment.

### **Recent Developments**

#### *Governmental Inquiries and Investigations and Stockholder Litigation*

See Note 6 to our condensed consolidated financial statements for a discussion of the recent governmental inquiry, investigations and subsequent stockholder litigation we are involved in. No assurances can be given as to the timing or outcome of these items.

#### *Health Care Reform*

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act ( PPACA ) and the Health Care and Education Reconciliation Act of 2010 ( HCERA ), which amends the PPACA (collectively, the Health Care Reform Bills ). The Health Care Reform Bills make a number of changes to Medicare payment rates, including the reinstatement of the 3% home health rural add-on, which began on April 1, 2010 (expiring January 1, 2016). The Health Care Reform Bills also include a systemic rebasing of the amount Centers for Medicare and Medicaid Services ( CMS ) reimburses for home health services, to be phased in over four years, beginning in 2014. We anticipate that many of the provisions of the Health Care Reform Bills may be subject to further clarification and modification through the rule-making process. It is uncertain at this time the effect the rebasing will have on our future results of operations or cash flows.

#### *Face-to-Face and Therapy Requirements*

In November 2010, CMS issued a rule which finalized two new provisions of the PPACA which ultimately were implemented April 1, 2011: (1) a face-to-face encounter requirement for home health and hospice and (2) changes in the therapy assessment schedule. As a condition for Medicare payment, the PPACA mandates that prior to certifying a patient s eligibility for the home health benefit, the certifying physician must document that he or she, or an allowed non-physician practitioner, has had a face-to-face encounter with the patient. The encounter must occur in the timeframe of 90 days prior to the start of care or 30 days after the start of care. Documentation regarding these encounters must be present on certifications.

The hospice rule for the implementation of a PPACA provision requires that a hospice physician or nurse practitioner have a face-to-face encounter with hospice patients during the 30 day period prior to the 180th-day recertification (third benefit period) and each subsequent recertification, and that the certifying hospice physician attest that such a visit took place.

The face-to-face encounter requirement for home health and hospice providers was to become effective January 1, 2011. However, due to concerns that some providers may need additional time to establish operational protocols necessary to comply with face-to-face encounter requirements, CMS delayed full enforcement of the requirements until April 1, 2011.

In addition, the November rule imposed important therapy assessment requirements. An assessment by a professional qualified therapist must take place at least once every 30 days during a therapy patient s course of treatment. For those qualified patients that require 13 or 19 therapy visits, a qualified therapist must perform the therapy service required, assess the patient, and measure and document effectiveness of additional visits. This requirement applies to each therapy discipline caring for the patient but the assessment must be performed close to, but no later than, the 13<sup>th</sup> and 19<sup>th</sup> visits.

*Payment*

On October 31, 2011, CMS issued a final rule to update and revise Medicare home health rates for calendar year 2012. The final rule includes a 1.4% market basket increase which includes the 1% reduction mandated by the Health Care Reform Bills and a negative 3.79% nominal change in case-mix adjustment. The net effect of these changes decreases the base rate by 2.4% to \$2,139. In addition, the final rule states that the Medicare home health rates for calendar year 2013 will include an additional negative 1.32% nominal change in case-mix adjustment. Based on our third quarter revenues, the decrease in the base rate would reduce home health revenue by approximately \$30.0 million. The final rule also shifts case mix points from high case mix and high therapy episodes to low case mix and non-therapy episodes. The shift from high therapy episodes will also negatively impact our revenues in 2012 in addition to the base rate decrease. The reduction will be dependent upon our therapy mix at the time the new rule is effective.

In August 2011, CMS issued a final rule to update and revise the Medicare hospice wage index for fiscal year 2012. The final rule includes a 3.0% market basket update, a 0.1% increase for the updated wage index data and the third year of the 7-year phase out of the budget neutrality adjustment factor of 0.6%. The net effect of the final rule, effective October 1, 2011, increases the base rate for 2012 by 2.5%. We do not expect this change to have a material impact on our future results of operations or financial condition.

**Table of Contents**

In addition to CMS final rule, if the Joint Select Committee on Deficit Reduction does not come to agreement by mid-November on solutions to cut the deficit, Medicare home health and hospice payments will decrease by 2% in 2013. If the Committee does reach an agreement, the impact to Medicare home health and hospice payments will be dependent on the agreement that is reached.

In July 2011, CMS issued a proposed rule that revised the Medicaid home health definition to add a requirement, similar to the finalized Medicare home health requirement, that a physician or non-physician practitioner perform a face-to-face encounter with the Medicaid eligible individual and the physician must document that the face-to-face encounter occurred. Under the proposed rule, the face-to-face encounter must occur no more than 90 days prior to the start of services under the Medicaid home health benefit or, in certain circumstances, within 30 days after the start of home health services. CMS has not issued a final rule as of the date of this filing.

**Results of Operations****Three-Month Period Ended September 30, 2011 Compared to the Three-Month Period Ended September 30, 2010**

During the three-month period September 30, 2011, we recorded a \$574.1 million estimated impairment charge of goodwill and other intangibles as a result of the decline in our market capitalization and forecasts during the quarter and incurred certain costs as defined below. These charges were offset by the release of a valuation allowance related to specific deferred tax assets.

During the three-month period ended September 30, 2010, we incurred costs associated with our 2010 exit activities as well as other certain costs (defined below). These charges were offset by the settlement of our Georgia indigent care liability for the years 2007 through 2009.

The following details these items (amounts in millions, except per share data):

	For the Three-Months Ended September 30, 2011				For the Three-Months Ended September 30, 2010				
	Financial Statement Line Item Impacted				Financial Statement Line Item Impacted				
	Other	Income Tax			Net	Other	Income Tax		
	Operating	Benefit	Net (Loss)	Diluted	Service	Operating	Benefit	Net (Loss)	Diluted
	Expenses	(Expense)	Income	EPS	Revenue	Expenses	(Expense)	Income	EPS
Georgia indigent care liability	\$	\$	\$	\$	\$ 3.7	\$	\$ (1.5)	\$ 2.2	\$ 0.08
CMS Bonus									
Exit activities						(6.9)	2.7	(4.2)	(0.15)
Goodwill and other intangibles impairment charge	(574.1)	139.5	(434.6)	(15.10)					
Valuation allowance adjustment		1.9	1.9	0.07					
Certain costs(1)	(2.7)	1.1	(1.6)	(0.06)		(3.1)	1.3	(1.8)	(0.06)
<b>Total</b>	<b>\$ (576.8)</b>	<b>\$ 142.5</b>	<b>\$ (434.3)</b>	<b>\$ (15.09)</b>	<b>\$ 3.7</b>	<b>\$ (10.0)</b>	<b>\$ 2.5</b>	<b>\$ (3.8)</b>	<b>\$ (0.13)</b>

- (1) Certain costs include acquisitions and related integration costs and legal expenses related to the United States Senate Committee on Finance inquiry and the SEC and DOJ investigations.

**Table of Contents**Consolidated

The following table summarizes our consolidated results of operations (amounts in millions):

	<b>For the Three-Month Periods Ended September 30,</b>	
	<b>2011</b>	<b>2010</b>
Net service revenue	\$ 374.9	\$ 404.7
Gross margin	169.2	198.4
<i>% of revenue</i>	<i>45.1%</i>	<i>49.0%</i>
Other operating expenses	152.4	161.3
<i>% of revenue</i>	<i>40.7%</i>	<i>39.9%</i>
Goodwill and other intangibles impairment charge	574.1	
Operating (loss) income	(557.3)	37.1
Income tax (benefit) expense	(135.6)	13.9
<i>Effective income tax rate</i>	<i>24.2%</i>	<i>39.0%</i>
Net (loss) income attributable to Amedisys, Inc.	\$ (423.7)	\$ 21.6

During the third quarter of 2011, we recorded a \$574.1 million estimated impairment charge of goodwill and other intangibles as a result of the decline in our market capitalization and forecasts during the quarter. In addition, we recognized a deferred tax benefit of \$139.5 million as a result of the estimated impairment charges.

Our net service revenue declined \$29.8 million from prior year primarily due to significant decrease in our home health division. Our operating income excluding the \$574.1 million estimated goodwill and other intangibles impairment charge, decreased \$20.3 million over prior year with approximately \$16.0 million resulting from the 2011 CMS rate cut impacting the home health division. In our efforts to mitigate the impact of the rate cut, we have reduced our other operating expenses excluding the estimated impairment charges by \$8.9 million and lowered our cost per visit. However, our admissions, recertifications and revenue per episode were below prior year performance on a total and same store basis which significantly impacted our operating performance. Our hospice division continued its growth in volumes and contribution and our recent acquisition of Beacon added significantly to the divisional portfolio.

Our fourth quarter performance will be impacted by two additional holidays and the impact of the final CMS rule on episodes in progress at December 31, 2011.

In addition to the \$139.5 million deferred tax benefit discussed above, income tax expense included a one-time favorable adjustment of \$1.9 million related to the release of a valuation allowance on specific deferred tax assets related to the utilization of state net operating losses during the third quarter of 2011. We estimate our effective tax rate to be 37% for the fiscal year 2011.

**Table of Contents****Home Health Division**

The following table summarizes our home health segment results of operations:

	For the Three-Month Periods Ended September 30,					
	2011			2010		
	Same Store	Start-ups/ Acquisitions	Total	Same Store	Other (1)	Total
<b>Financial Information (in millions):</b>						
Episodic-based revenue	286.6	4.4	<b>291.0</b>	336.7	12.5	<b>349.2</b>
Nonepisodic-based revenue	19.0	0.4	<b>19.4</b>	18.4	0.9	<b>19.3</b>
Net service revenue	305.6	4.8	<b>310.4</b>	355.1	13.4	<b>368.5</b>
<b>Same store episodic-based revenue growth (2)</b>	<b>(15)%</b>			<b>(1)%</b>		
Cost of service	167.4	3.3	<b>170.7</b>	175.9	10.3	<b>186.2</b>
Gross margin	138.2	1.5	<b>139.7</b>	179.2	3.1	<b>182.3</b>
Other operating expenses	79.5	2.7	<b>82.2</b>	84.6	16.3	<b>100.9</b>
Operating income before impairment charge (5)	\$ 58.7	\$ (1.2)	\$ <b>57.5</b>	\$ 94.6	\$ (13.2)	\$ <b>81.4</b>
<b>Key Statistical Data:</b>						
<b>Admissions:</b>						
Episodic-based	57,161	984	<b>58,145</b>	60,797	2,675	<b>63,472</b>
Nonepisodic-based	10,893	211	<b>11,104</b>	9,849	563	<b>10,412</b>
Total admissions	68,054	1,195	<b>69,249</b>	70,646	3,238	<b>73,884</b>
<b>Same store episodic-based admission growth (2)</b>	<b>(6)%</b>			<b>6%</b>		
<b>Recertifications:</b>						
Episodic-based	43,295	450	<b>43,745</b>	44,470	1,461	<b>45,931</b>
Nonepisodic-based	4,283	38	<b>4,321</b>	4,464	130	<b>4,594</b>
Total recertifications	47,578	488	<b>48,066</b>	48,934	1,591	<b>50,525</b>
<b>Same store episodic-based recertification growth (2)</b>	<b>(3)%</b>			<b>(14)%</b>		
<b>Episodic-based completed episodes</b>	96,661	1,359	<b>98,020</b>	100,743	4,254	<b>104,997</b>
<b>Visits:</b>						
Episodic-based	1,880,880	25,920	<b>1,906,800</b>	1,979,497	72,870	<b>2,052,367</b>
Nonepisodic-based	203,016	3,597	<b>206,613</b>	200,009	8,232	<b>208,241</b>
Total visits	2,083,896	29,517	<b>2,113,413</b>	2,179,506	81,102	<b>2,260,608</b>
Cost per visit	\$ 80.32	\$ 110.25	\$ <b>80.74</b>	\$ 80.71	\$ 127.16	\$ <b>82.38</b>

<b>Average episodic-based revenue per completed episode (3)</b>	\$ 2,972	\$ 3,166	\$ <b>2,975</b>	\$ 3,301	\$ 3,118	\$ <b>3,294</b>
<b>Episodic-based visits per completed episode (4)</b>	18.7	17.6	<b>18.7</b>	19.2	17.2	<b>19.1</b>

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same store episodic-based revenue, admissions or recertifications growth is the percent increase (decrease) in our same store episodic-based revenue, admissions or recertifications for the period as a percent of the same store episodic-based revenue, admissions or recertifications of the prior period.
- (3) Average episodic-based revenue per completed episode is the average episodic-based revenue earned for each episodic-based completed episode of care.
- (4) Episodic-based visits per completed episode is the home health episodic-based visits on completed episodes divided by the home health episodic-based episodes completed during the period.
- (5) Operating loss of \$516.6 million on a GAAP basis for the three-month period ended September 30, 2011.

*Net Service Revenue*

Our home health revenue is driven by the volume of admissions and recertifications and the revenue per episode on episodes completed and in progress during the quarter. We experienced significant declines in all of these revenue metrics which contributed to a \$54.4 million decline in our home health net service revenue excluding the \$3.7 million for the settlement of our Georgia indigent care liability we recognized during the three month period ended September 30, 2010.

**Table of Contents**

Admissions and recertifications accounted for approximately \$26.0 million of the decline as we experienced negative same store episodic-based admissions and recertification growth during the quarter. These declines include the impact of agencies we closed or merged in 2010. We believe our admission volumes were negatively impacted by the CMS face-to-face requirements. However, we believe that we have successfully implemented this regulation and have recorded a reserve of approximately \$2.0 million as an estimate of our failure to receive certifications from the physicians for admissions currently in our patient census. While we cannot fully measure the impact of lower admissions due to the unwillingness of physicians to refer to home health as a result of this regulation, we do believe it has impacted current admissions and it could continue to impact admissions in subsequent quarters. While our recertifications as a percentage of completed episodes increased approximately 1% over prior year, the number of episodic recertifications has decreased due to an overall decline in patient census.

Our revenue per episode decline of 10% has resulted in approximately a \$28.0 million decrease in revenue with approximately \$16.0 million as a result of the 5.2% CMS rate cut for 2011 with the remainder due to a reduction in the therapy needs of our patients and the impact of the new CMS therapy assessment regulations effective April 1, 2011. We had approximately 30,000 non-billable therapy visits due to our failure to meet the requirements of the regulation which resulted in an estimated \$5.0 million reduction in revenue. We experienced a significant decline in the number of non-billable therapy visits in the later part of the quarter. We anticipate continuing to have some negative impact due to the operational difficulty in managing this regulation; however, we expect a reduction in the number of non-billable therapy visits in the fourth quarter of 2011.

*Cost of Service, excluding Depreciation and Amortization*

The decline in cost per visit is due primarily to our conversion of therapists to our pay per visit models, our focus on productivity, our portfolio realignment and a decline in therapy visits. We anticipate our same store cost per visit to remain stable, absent the impact of holidays, however, any material change in the level of service needed by our patients could impact this metric.

*Other Operating Expenses*

Our other operating expenses decreased \$18.7 million with \$14.3 million (includes \$5.4 million in certain costs) due to closures. The remainder is due to continued efforts to reduce costs in our portfolio.

**Hospice Division**

The following table summarizes our hospice segment results of operations:

	For the Three-Month Periods Ended September 30,					
	2011			2010		
	Same Store	Start-ups/ Acquisitions	Total	Same Store	Other (1)	Total
<b>Financial Information (in millions):</b>						
Medicare revenue	\$ 38.3	\$ 22.3	\$ 60.6	\$ 32.7	\$ 1.5	\$ 34.2
Non-Medicare revenue	2.5	1.4	3.9	2.0		2.0
Net service revenue	40.8	23.7	64.5	34.7	1.5	36.2
<b>Same store Medicare revenue growth (2)</b>	<b>17%</b>			<b>14%</b>		
Cost of service	21.6	13.4	35.0	18.6	1.5	20.1
Gross margin	19.2	10.3	29.5	16.1		16.1
Other operating expenses	7.9	5.4	13.3	7.5	2.3	9.8
Operating income	\$ 11.3	\$ 4.9	\$ 16.2	\$ 8.6	\$ (2.3)	\$ 6.3

***Key Statistical Data:***

Hospice admits	3,070	1,538	4,608	2,657	125	2,782
----------------	-------	-------	-------	-------	-----	-------

Edgar Filing: AMEDISYS INC - Form 10-Q

Hospice days	311,034	139,922	<b>450,956</b>	263,233	10,756	<b>273,989</b>
Average daily census	3,381	1,521	<b>4,902</b>	2,861	117	<b>2,978</b>
Revenue per day	\$ 131.46	\$ 169.29	<b>\$ 143.20</b>	\$ 131.76	\$ 137.17	<b>\$ 131.97</b>
Cost of service per day	\$ 69.39	\$ 95.18	<b>\$ 77.37</b>	\$ 71.00	\$ 128.95	<b>\$ 73.28</b>
Average length of stay	94	70	<b>86</b>	88	79	<b>87</b>

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same Store Medicare revenue growth is the percent increase in our same store Medicare revenue for the period as a percent of the same store Medicare revenue of the prior period



**Table of Contents***Net Service Revenue*

Our hospice revenue increased \$28.3 million with \$6.1 million from our same store agencies, \$0.9 million from our start-up agencies and \$22.8 million from our acquisitions (\$21.7 million from our Beacon acquisition) offset by \$1.5 million from agencies we closed or merged in 2010. The fourth quarter will benefit from the hospice rate increase effective October 1, 2011.

Hospice revenue is primarily impacted by average daily census, levels of care and payment rates. Our 2011 revenue includes an increase related to an annual hospice rate increase effective October 1, 2010, which was approximately 1.8%. Additionally, our 2011 hospice revenue is net of a \$0.8 million hospice cap adjustment, a decrease of \$0.3 million from 2010. Our same store average daily census is up 18% over prior year as we have exceeded same store average daily census in excess of 15% for the past four quarters.

*Cost of Service excluding Depreciation and Amortization*

Our hospice cost of service increased \$14.9 million (74%) due to the 65% increase in our average daily census over 2010 as a result of our acquisition of Beacon. Our hospice clinicians are generally paid on a salaried basis, and our agencies are staffed based on the average census of the agency.

*Other Operating Expenses*

Our other operating expenses have remained stable on a same store basis. The increase in total other operating expenses is due to our Beacon acquisition.

***Nine-Month Period Ended September 30, 2011 Compared to the Nine-Month Period Ended September 30, 2010***

During the nine-month period September 30, 2011, we recorded a \$574.1 million estimated impairment charge of goodwill and other intangibles as a result of the decline in our market capitalization, third quarter results and recent forecasts during the quarter and incurred certain costs as defined below. These charges were offset by the release of a valuation allowance related to specific deferred tax assets, the reversal of accrued bonuses and a CMS bonus payment as the result of the pay for performance demonstration.

During the nine-month period ended September 30, 2010, we incurred costs associated with our 2010 exit activities as well as other certain costs (defined below). These charges were offset by the settlement of our Georgia indigent care liability for the years 2007 through 2009, the reversal of accrued bonuses and a CMS bonus payment.

The following details these items (amounts in millions, except per share data):

	For the Nine-Months Ended September 30, 2011					For the Nine-Months Ended September 30, 2010				
	Financial Statement Line Item Impacted					Financial Statement Line Item Impacted				
	Net Service Revenue	Other Operating Expenses	Income Tax Benefit (Expense)	Net (Loss) Income	Diluted EPS	Net Service Revenue	Other Operating Expenses	Income Tax Benefit (Expense)	Net (Loss) Income	Diluted EPS
Bonus reversal	\$	\$ 1.5	\$ (0.6)	\$ 0.9	\$ 0.03	\$	\$ 3.1	\$ (1.2)	\$ 1.9	\$ 0.07
Georgia indigent care liability						3.7		(1.5)	2.2	0.08
CMS Bonus	4.7		(1.8)	2.9	0.10	3.6		(1.4)	2.2	0.08
Exit activities		(1.1)	0.4	(0.7)	(0.02)		(8.4)	3.3	(5.1)	(0.18)
Goodwill and other intangibles impairment charge		(574.1)	139.5	(434.6)	(15.18)					
Valuation allowance adjustment			1.9	1.9	0.07					
Certain costs (1)		(8.7)	3.5	(5.2)	(0.18)		(9.5)	3.7	(5.8)	(0.21)
Total	\$ 4.7	\$ (582.4)	\$ 142.9	\$ (434.8)	\$ (15.18)	\$ 7.3	\$ (14.8)	\$ 2.9	\$ (4.6)	\$ (0.16)

## Edgar Filing: AMEDISYS INC - Form 10-Q

- (1) Certain costs include acquisitions and related integration costs and legal expenses related to the United States Senate Committee on Finance inquiry and the SEC and DOJ investigations.

**Table of Contents**Consolidated

The following table summarizes our consolidated results of operations (amounts in millions):

	For the Nine-Month Periods Ended September 30,	
	2011	2010
Net service revenue	\$ 1,112.9	\$ 1,240.0
Gross margin	522.9	620.3
<i>% of revenue</i>	<i>47.0%</i>	<i>50.0%</i>
Other operating expenses	440.6	465.2
<i>% of revenue</i>	<i>39.6%</i>	<i>37.5%</i>
Goodwill and other intangibles impairment charge	574.1	
<b>Operating (loss) income</b>	<b>(491.8)</b>	<b>155.1</b>
Income tax (benefit) expense	(111.4)	58.2
<i>Effective income tax rate</i>	<i>22.4%</i>	<i>39.0%</i>
Net (loss) income attributable to Amedisys, Inc.	\$ (386.8)	\$ 90.5

During the third quarter of 2011, we recorded a \$574.1 million estimated impairment charge of goodwill and other intangibles as a result of the decline in our market capitalization and forecasts during the quarter. In addition, we recognized a deferred tax benefit of \$139.5 million as a result of the estimated impairment charges.

Our operating income excluding the \$574.1 million estimated goodwill and other intangibles impairment charge declined \$72.8 million with approximately \$54.0 million of the decline resulting from the 2011 CMS rate cut impacting the home health division. We were able to partially mitigate this impact by a \$17.9 million increase in operating income from our hospice division and a \$48.8 million reduction in other operating expenses excluding the estimated impairment charges from our home health division. However, our home health division experienced a decline in episodic volumes and declines in revenue per episode in excess of the rate cut which further impacted our performance. Additionally, we had an increase of \$19.6 million in our corporate support functions primarily related to additional salary costs, depreciation and amortization and legal fees.

In addition to the \$139.5 million deferred tax benefit discussed above, income tax expense included a one-time favorable adjustment of \$1.9 million related to the release of a valuation allowance on specific deferred tax assets related to the utilization of state net operating losses during the third quarter of 2011. We estimate our effective tax rate to be 37% for the fiscal year 2011.

**Table of Contents****Home Health Division**

The following table summarizes our home health segment results of operations:

	For the Nine-Month Periods Ended September 30,					
	2011			2010		
	Same Store	Start-ups/ Acquisitions	Total	Same Store	Other (1)	Total
<b>Financial Information (in millions):</b>						
Episodic-based revenue	889.6	16.3	<b>905.9</b>	1,040.6	39.6	<b>1,080.2</b>
Nonepisodic-based revenue	55.4	1.0	<b>56.4</b>	54.2	2.6	<b>56.8</b>
Net service revenue	945.0	17.3	<b>962.3</b>	1,094.8	42.2	<b>1,137.0</b>
<b>Same store episodic-based revenue growth (2)</b>	<b>(15)%</b>			<b>6%</b>		
Cost of service	498.5	10.6	<b>509.1</b>	532.1	31.8	<b>563.9</b>
Gross margin	446.5	6.7	<b>453.2</b>	562.7	10.4	<b>573.1</b>
Other operating expenses	235.6	9.2	<b>244.8</b>	253.1	40.5	<b>293.6</b>
Operating income before impairment charge (5)	\$ 210.9	\$ (2.5)	<b>\$ 208.4</b>	\$ 309.6	\$ (30.1)	<b>\$ 279.5</b>
<b>Key Statistical Data:</b>						
<b>Admissions:</b>						
Episodic-based	176,118	3,487	<b>179,605</b>	183,668	8,158	<b>191,826</b>
Nonepisodic-based	31,797	604	<b>32,401</b>	28,906	1,586	<b>30,492</b>
Total admissions	207,915	4,091	<b>212,006</b>	212,574	9,744	<b>222,318</b>
<b>Same store episodic-based admission growth (2)</b>	<b>(4)%</b>			<b>7%</b>		
<b>Recertifications:</b>						
Episodic-based	130,330	1,361	<b>131,691</b>	138,553	4,663	<b>143,216</b>
Nonepisodic-based	12,893	118	<b>13,011</b>	13,872	354	<b>14,226</b>
Total recertifications	143,223	1,479	<b>144,702</b>	152,425	5,017	<b>157,442</b>
<b>Same store episodic-based recertification growth (2)</b>	<b>(6)%</b>			<b>(8)%</b>		
<b>Episodic-based completed episodes</b>	294,195	4,488	<b>298,683</b>	306,607	12,906	<b>319,513</b>
<b>Visits:</b>						
Episodic-based	5,689,997	86,571	<b>5,776,568</b>	6,028,910	222,163	<b>6,251,073</b>
Nonepisodic-based	600,382	10,538	<b>610,920</b>	599,735	29,861	<b>629,596</b>
Total visits	6,290,379	97,109	<b>6,387,488</b>	6,628,645	252,024	<b>6,880,669</b>
Cost per visit	\$ 79.25	\$ 109.33	<b>\$ 79.70</b>	\$ 80.28	\$ 125.99	<b>\$ 81.95</b>

<b>Average episodic-based revenue per completed episode (3)</b>	\$ 3,011	\$ 3,118	\$ <b>3,013</b>	\$ 3,322	\$ 3,193	\$ <b>3,317</b>
<b>Episodic-based visits per completed episode (4)</b>	18.7	17.7	<b>18.7</b>	19.1	17.4	<b>19.0</b>

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same store episodic-based revenue, admissions or recertifications growth is the percent increase (decrease) in our same store episodic-based revenue, admissions or recertifications for the period as a percent of the same store episodic-based revenue, admissions or recertifications of the prior period.
- (3) Average episodic-based revenue per completed episode is the average episodic-based revenue earned for each episodic-based completed episode of care.
- (4) Episodic-based visits per completed episode is the home health episodic-based visits on completed episodes divided by the home health episodic-based episodes completed during the period.
- (5) Operating loss of \$365.7 million on a GAAP basis for the nine-month period ended September 30, 2011.

**Table of Contents***Net Service Revenue*

We experienced a decline in all three revenue performance metrics, as our admissions, recertifications and revenue per episode declined over prior year. As mentioned, approximately \$54.0 million of the \$174.7 million decline in revenue is due to the 5.2% CMS rate cut for 2011.

Lower admissions and recertifications accounted for approximately \$79.0 million of the decline. We have experienced sequential declines in same store admissions for 2011. We believe the impact of the face-to-face requirements has added additional pressure to admission growth during the second and third quarters of 2011. The primary factor in our decline in recertifications is the decline in our patient census as our recertification percentage of completed episodes is down less than 1% from 2010.

Overall, revenue per episode decreased by 9% as a result of the 5.2% CMS rate cut for 2011 with the additional reduction primarily due to a reduction in the therapy needs of our patients and the impact of the therapy functional assessment regulation which resulted in a reduction in net service revenue of approximately \$9.0 million. We saw a decline in the number of non-billable therapy visits in the later part of the third quarter. We anticipate the impact of this regulation to decline into the fourth quarter of 2011.

*Cost of Service, excluding Depreciation and Amortization*

Our home health cost of service decreased \$54.8 million as we performed 493,181 fewer visits which accounted for \$40.4 million of the decrease with the remainder from the \$2.25 decrease in cost per visit. The cost per visit improvement is due to our portfolio realignment as well as a focus on productivity and conversion of salaried clinicians to our pay per visit model. Except for the impact of additional holidays in the fourth quarter, we expect our cost per visit to remain stable.

*Other Operating Expenses*

Our other operating expenses excluding the estimated impairment charges decreased \$48.8 million in total and \$17.5 million on a same store basis with the primary drivers being a decline in salary and benefits and additional cost reductions in our remaining portfolio. Additionally, 2010 included approximately \$6.9 million in certain costs related to agencies we closed or merged in 2010

**Hospice Division**

The following table summarizes our hospice segment results of operations:

	For the Nine-Month Periods Ended September 30, 2011			2010		
	Same Store	Start-ups/ Acquisitions	Total	Same Store	Other (1)	Total
<b><i>Financial Information (in millions):</i></b>						
Medicare revenue	\$ 111.5	\$ 29.7	\$ 141.2	\$ 93.0	\$ 4.3	\$ 97.3
Non-Medicare revenue	7.5	1.9	9.4	5.5	0.2	5.7
Net service revenue	119.0	31.6	150.6	98.5	4.5	103.0
<b>Same store Medicare revenue growth (2)</b>	<b>20%</b>			<b>22%</b>		
Cost of service	62.2	18.7	80.9	51.6	4.2	55.8
Gross margin	56.8	12.9	69.7	46.9	0.3	47.2
Other operating expenses	23.0	8.3	31.3	22.1	4.6	26.7
Operating income	\$ 33.8	\$ 4.6	\$ 38.4	\$ 24.8	\$ (4.3)	\$ 20.5

***Key Statistical Data:***

Edgar Filing: AMEDISYS INC - Form 10-Q

Hospice admits	9,298	2,247	<b>11,545</b>	7,962	487	<b>8,449</b>
Hospice days	890,258	188,796	<b>1,079,054</b>	736,289	32,391	<b>768,680</b>
Average daily census	3,261	692	<b>3,953</b>	2,697	119	<b>2,816</b>
Revenue per day	\$ 133.67	\$ 167.51	\$ <b>139.59</b>	\$ 133.72	\$ 138.61	\$ <b>133.93</b>
Cost of service per day	\$ 69.73	\$ 98.98	\$ <b>74.84</b>	\$ 70.14	\$ 127.13	\$ <b>72.54</b>
Average length of stay	90	70	<b>86</b>	88	69	<b>87</b>

- (1) Agencies for the prior period which are not considered same store agencies (i.e. agencies closed or consolidated in current or prior period or unopened startups).
- (2) Same Store Medicare revenue growth is the percent increase in our same store Medicare revenue for the period as a percent of the same store Medicare revenue of the prior period

**Table of Contents***Net Service Revenue*

Our hospice revenue increased \$47.6 million with \$20.5 million from our same store agencies, \$2.3 million from our start-up agencies and \$29.3 million from our acquisitions offset by \$4.5 million from agencies we closed or merged in 2010. Our Beacon acquisition added \$27.3 million.

Hospice revenue is primarily impacted by average daily census, levels of care and payment rates. Our 2011 revenue includes an increase related to annual hospice rate increase effective October 1, 2010, which was approximately 1.8%. The growth in our same store revenue is driven by a 21% increase in average daily census. Additionally, our 2011 hospice revenue is net of a \$2.1 million hospice cap adjustment, an increase of \$0.4 million from 2010.

*Cost of Service excluding Depreciation and Amortization*

Our hospice cost of service increased \$25.1 million (45%) due to the 40% increase in our average daily census over 2010. Our hospice clinicians are generally paid on a salaried basis, and our agencies are staffed based on the average census of the agency.

*Other Operating Expenses*

Our other operating expenses as a percent of revenue decreased 5.1% as a result of cost reductions in our portfolio. The hospice division did benefit from a \$0.7 million reduction in bad debt expense due to significant improvement in cash collections. As our hospice division continues to grow, we do expect to add additional resources in order to meet the needs of our patients and support the growth in the division.

**LIQUIDITY AND CAPITAL RESOURCES***Cash Flows for the Nine-Month Period Ended September 30, 2011 Compared to the Nine-Month Period Ended September 30, 2010*

The following table summarizes our cash flows for the periods indicated (amounts in millions):

	<b>For the Nine-Month Periods Ended September 30,</b>	
	<b>2011</b>	<b>2010</b>
Cash provided by operating activities	\$ 104.3	\$ 172.6
Cash used in investing activities	(168.7)	(41.7)
Cash used in financing activities	(26.4)	(37.4)
Net increase in cash and cash equivalents	(90.8)	93.5
Cash and cash equivalents at beginning of period	120.3	34.5
Cash and cash equivalents at end of period	\$ 29.5	\$ 128.0

Cash provided by operating activities decreased \$68.3 million during 2011 compared to 2010, primarily due to the reduction in reimbursement and a decline in operating performance as well as an increase in our days revenue outstanding. The recognition of the estimated goodwill and intangible asset impairment charge of \$574.1 million, which resulted in the net loss for our nine-month period ended September 30, 2011, is non-cash in nature and therefore had no impact on our cash flow from operations.

Cash used in investing activities increased \$127.0 million during 2011 compared to 2010 primarily due to our acquisition of Beacon (\$126.0 million).

Cash used in financing activities decreased \$11.0 million during 2011 compared to 2010, primarily due to a decrease in the exercise of stock options, which was offset by a decrease in repayments on our long-term obligations and the decrease in the repurchase of company stock. We decreased our outstanding long-term obligations net of borrowings by \$28.7 million from December 31, 2010.

*Liquidity*



## Edgar Filing: AMEDISYS INC - Form 10-Q

Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program; however, from time to time, we can and do obtain additional sources of liquidity through sales of our equity or by incurrence of additional indebtedness. As of September 30, 2011, we had \$29.5 million in cash and cash equivalents and \$231.3 million in availability under our \$250.0 million Revolving Credit Facility.

## Edgar Filing: AMEDISYS INC - Form 10-Q

During the nine-month period ended September 30, 2011, we spent \$38.6 million in routine capital expenditures, which primarily included equipment, furniture and computer software and \$16.0 million in capital expenditures related to the implementation of our enterprise resource planning system and a company-wide refresh of computer hardware.

Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements over the next twelve months and into the foreseeable future. However, our future liquidity will be impacted by the 2012 proposed reimbursement and any future reductions in reimbursement. We are dependent on our ability to reduce costs and/or grow our business in order to offset the impact of future reimbursement reductions.

**Table of Contents*****Outstanding Patient Accounts Receivable***

Our patient accounts receivable, net increased \$9.7 million from December 31, 2010 to September 30, 2011 primarily due to the acquisition of Beacon which resulted in an increase of \$13.4 million. Our cash collection as a percentage of revenue was 104.0% for the three-month periods ended September 30, 2011 and 99.3% for the three-month periods ended December 31, 2010. Our days revenue outstanding, net has increased by 3.1 days since December 31, 2010 primarily due to billing delays caused by the new face-to-face and functional assessment requirements.

Our patient accounts receivable includes unbilled receivables, which are aged based upon our initial service date. At September 30, 2011, the unbilled patient accounts receivable, as a percentage of gross patient accounts receivable, was 27.5%, or \$48.4 million compared to 28.3% or \$47.9 million at December 31, 2010. We monitor unbilled receivables on an agency by agency basis to ensure that all efforts are made to bill claims within timely filing deadlines. The timely filing deadlines vary by state for Medicaid-reimbursable services and among insurance companies.

Our provision for estimated revenue adjustments (which is deducted from our service revenue to determine net service revenue) and provision for doubtful accounts were as follows for the periods indicated (in millions). We fully reserve for both our Medicare and other patient accounts receivable that are aged over 360 days.

	For the Three-Month Periods Ended September 30,		For the Nine-Month Periods Ended September 30,	
	2011	2010	2011	2010
Provision for estimated revenue adjustments	\$ 3.3	\$ 2.7	\$ 8.2	\$ 4.4
Provision for doubtful accounts	4.6	5.3	9.9	14.1
<b>Total</b>	<b>\$ 7.9</b>	<b>\$ 8.0</b>	<b>\$ 18.1</b>	<b>\$ 18.5</b>
As a percent of revenue	2.1%	2.0%	1.6%	1.5%

**Table of Contents**

The following schedule details our patient accounts receivable, net of estimated revenue adjustments, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding, net):

	0-90	91-180	181-365	Over 365	Total
<b>At September 30, 2011:</b>					
Medicare patient accounts receivable, net (1)	\$ 89.1	\$ 19.7	\$ 2.6	\$	\$ 111.4
Other patient accounts receivable:					
Medicaid	11.6	1.7	0.9	0.2	14.4
Private	26.9	8.7	5.4	2.5	43.5
Total	\$ 38.5	\$ 10.4	\$ 6.3	\$ 2.7	\$ 57.9
Allowance for doubtful accounts (2)					(18.1)
Non-Medicare patient accounts receivable, net					\$ 39.8
Total patient accounts receivable, net					\$ 151.2
Days revenue outstanding, net (3)					35.9
	0-90	91-180	181-365	Over 365	Total
<b>At December 31, 2010:</b>					
Medicare patient accounts receivable, net (1)	\$ 89.4	\$ 16.4	\$ 1.3	\$	\$ 107.1
Other patient accounts receivable:					
Medicaid	6.0	2.2	2.0	0.1	10.3
Private	27.2	9.9	7.0	1.0	45.1
Total	\$ 33.2	\$ 12.1	\$ 9.0	\$ 1.1	\$ 55.4
Allowance for doubtful accounts (2)					(21.0)
Non-Medicare patient accounts receivable, net					\$ 34.4
Total patient accounts receivable, net					\$ 141.5
Days revenue outstanding, net (3)					32.8

(1) The following table summarizes the activity and ending balances in our estimated revenue adjustments (amounts in millions), which is recorded to reduce our Medicare outstanding patient accounts receivable to their estimated net realizable value, as we do not estimate an allowance for doubtful accounts for our Medicare claims.

For the Three-Month Period Ended      For the Three-Month Period Ended      For the Nine-Month Period Ended      For the Nine-Month Period Ended

Edgar Filing: AMEDISYS INC - Form 10-Q

	September 30, 2011	December 31, 2010	September 30, 2011	December 31, 2010
Balance at beginning of period	\$ 7.2	\$ 6.3	\$ 6.5	\$ 6.9
Provision for estimated revenue adjustments	3.3	2.6	8.2	6.8
Write offs	(3.7)	(2.4)	(9.0)	(7.2)
Acquired through acquisitions			1.1	
Balance at end of period	\$ 6.8	\$ 6.5	\$ 6.8	\$ 6.5

Our estimated revenue adjustments were 5.7% of our outstanding Medicare patient accounts receivable at September 30, 2011 and December 31, 2010, respectively.

- (2) The following table summarizes the activity and ending balances in our allowance for doubtful accounts (amounts in millions), which is recorded to reduce only our Medicaid and private outstanding patient accounts receivable to their estimated net realizable value.

	For the Three-Month Period Ended September 30, 2011	For the Three-Month Period Ended December 31, 2010	For the Nine-Month Period Ended September 30, 2011	For the Nine-Month Period Ended December 31, 2010
Balance at beginning of period	\$ 18.2	\$ 23.0	\$ 21.0	\$ 25.8
Provision for doubtful accounts	4.6	5.1	9.9	14.9
Write offs	(4.7)	(7.1)	(14.1)	(19.7)
Acquired through acquisitions			1.3	
Balance at end of period	\$ 18.1	\$ 21.0	\$ 18.1	\$ 21.0

Our allowance for doubtful accounts was 31.3% and 37.8% of our outstanding Medicaid and private patient accounts receivable at September 30, 2011 and December 31, 2010, respectively.

- (3) Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts receivable (i.e. net of estimated revenue adjustments and allowance for doubtful accounts) at September 30, 2011 and December 31, 2010 by our average daily net patient revenue for the three-month periods ended September 30, 2011 and December 31, 2010, respectively.

**Indebtedness**

*Revolving Credit Facility*

On May 26, 2011, we entered into a First Amendment to our \$250.0 Million Revolving Credit Facility (the "First Amendment"). Under the terms of the First Amendment, (i) the financial covenant baskets relating to permitted Investments in Joint Ventures and other Investments were increased to give the Company greater flexibility, (ii) there was a non-substantive, clarifying amendment to the definition of Permitted Acquisition and (iii) certain other agreements, obligations and representations and warranties of the

## **Table of Contents**

parties thereto were amended, modified and/or supplemented. In connection with the execution of the First Amendment, each existing guarantor under the Credit Agreement consented to the terms of the First Amendment.

Our weighted-average interest rate for our five year Term Loan for the three and nine-month periods ended September 30, 2011 was 1.0% as compared to 1.1% for the three and nine-month periods ended September 30, 2010.

As of September 30, 2011, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.9 and our fixed charge coverage ratio was 1.7.

As of September 30, 2011, our availability under our \$250.0 million Revolving Credit Facility was \$231.3 million as we had \$18.7 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

## **Inflation**

We do not believe that inflation has significantly impacted our results of operations.

## **Critical Accounting Policies**

See Part II, Item 7 Critical Accounting Policies and our consolidated financial statements and related notes in Part IV, Item 15 of our 2010 Annual Report on Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting policies include revenue recognition; patient accounts receivable; insurance; goodwill and intangible assets; and income taxes. There have not been any changes to our significant accounting policies or their application since we filed our 2010 Annual Report on Form 10-K.

## **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our Revolving Credit Facility and Term Loan carry a floating interest rate which is tied to the Eurodollar rate (i.e. LIBOR) and the Prime Rate and, therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows will be exposed to changes in interest rates. As of September 30, 2011, the total amount of outstanding debt subject to interest rate fluctuations was \$45.0 million. A 1.0% interest rate increase would increase interest expense by approximately \$0.5 million annually.

## **ITEM 4. CONTROLS AND PROCEDURES**

### *Evaluation of Disclosure Controls and Procedures*

We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.

In connection with the preparation of this Quarterly Report on Form 10-Q, as of September 30, 2011, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.

Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2011, the end of the period covered by this Quarterly Report.

### *Changes in Internal Controls*

On January 1, 2011, the Company implemented two modules of a new enterprise resource planning system, PeopleSoft Financials and PeopleSoft Human Capital Management. This implementation was part of our focus on upgrading and enhancing our financial systems and was

## Edgar Filing: AMEDISYS INC - Form 10-Q

not in response to any internal control deficiencies. In connection with this system implementation, we are in the process of updating our internal controls over financial reporting, as necessary, to accommodate modifications to our business and accounting processes. We do not believe this implementation will have an adverse affect on our internal controls over financial reporting.

---

## **Table of Contents**

There were no other changes in internal control over financial reporting during the quarter ended September 30, 2011, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

### ***Inherent Limitations on Effectiveness of Controls***

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls' effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2011, the end of the period covered by this Quarterly Report.

## **PART II. OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

See Note 6 to the condensed consolidated financial statements for information concerning our legal proceedings.

### **ITEM 1A. RISK FACTORS**

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A "Risk Factors" of our 2010 Annual Report on Form 10-K. The risks described in our 2010 Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There have been no material changes in our risk factors from those disclosed in our 2010 Annual Report on Form 10-K, except for the following:

***The economic downturn, any deepening of the economic downturn, continued deficit spending by the Federal government, any failure by the Federal government to raise the debt ceiling, causing the U.S. Treasury to cease making payments under government programs in which we participate, any failure to complete the Federal budget process and fund Federal government operations, resulting in a Federal government shutdown, as well as state budget pressures may result in a reduction in payments and covered services.***

Adverse developments in the United States and global economies, continued deficit spending due to economic conditions, bailout programs directed at specific industries or other governmental measures could lead to a reduction in Federal government expenditures, including governmentally funded programs in which we participate, such as Medicare and Medicaid. In addition, if at any time the Federal government is not able to meet its debt payments unless the Federal debt ceiling is raised, and legislation increasing the debt ceiling is not enacted, the Federal government may stop or delay making payments on its obligations, including funding for government programs in which we participate, such as Medicare and Medicaid. Failure for the government to make payments under these programs could have a material adverse effect on our business and our consolidated financial condition, results of operations and cash flows. Further, any failure by the United States Congress to complete the Federal budget process and fund government operations may result in a Federal government shutdown, potentially causing us to incur substantial costs without reimbursement under the Medicare program, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

Historically, state budget pressures have resulted in reductions in state spending. Given that Medicaid outlays are a significant component of state budgets, we can expect continuing cost containment pressures on Medicaid outlays for our services. In addition, continued unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.





**Table of Contents**

*We are exposed to intangible asset risk; specifically, our goodwill may become impaired.*

We have determined that goodwill and other intangible assets related to our home health reporting unit was impaired and we recorded an estimated non-cash goodwill and other intangible assets impairment charge of \$574.1 million for the home health reporting unit. We recorded this charge based on a preliminary assessment because we are continuing to evaluate the valuations of our tangible and intangible assets and the allocation of fair value to our home health reporting unit's assets and liabilities. We expect to complete our assessment during the fourth quarter of fiscal year 2011. In addition, a further significant and sustained decline in our stock price and market capitalization, a significant decline in our expected future cash flows, a significant adverse change in the business climate or slower growth rates could result in the need to perform an impairment analysis under Accounting Standard Codification (ASC) Topic 350 Intangibles—Goodwill and Other in future periods. If we were to conclude that a future write down of our goodwill is necessary, then we would record the appropriate charge, which could result in material charges that are adverse to our consolidated financial condition and results of operations. See Note 4 Goodwill and Other Intangibles Assets, Net to our condensed consolidated financial statements for additional information on the impairment.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended September 30, 2011:

Period	(a) Total Number of Shares (or Units) Purchased	(b) Average Price Paid per Share (or Unit)	(c) Total Number of Share (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
July 1, 2011 to July 31, 2011	1,651	\$ 26.93		
August 1, 2011 to August 31, 2011	668	\$ 19.46		\$
September 1, 2011 to September 30, 2011	180	\$ 15.37		
Total	2,499(1)	\$ 24.10		\$

(1) Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 Omnibus Incentive Compensation Plan

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. RESERVED****ITEM 5. OTHER INFORMATION**

None.

**Table of Contents****ITEM 6. EXHIBITS**

The exhibits marked with the cross symbol ( ) are filed and the exhibits marked with the double cross symbol ( ) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (\*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

<b>Exhibit Number</b>	<b>Document Description</b>	<b>Report or Registration Statement</b>	<b>SEC File or Registration Number</b>	<b>Exhibit or Other Reference</b>
3.1	Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007	The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007	0-24260	3.1
3.2	Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009	The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009	0-24260	3.2
4.1	Common Stock Specimen	The Company's Registration Statement on Form S-3 filed August 20, 2007	333-145582	4.8
4.2	Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) \$35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) \$30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) \$35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.1
4.3	Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.2
4.4	Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.3
4.5	Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.4
31.1	Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002			
31.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002			
32.1	Certification of William F. Borne, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002			
32.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002			
101.INS	XBRL Instance			
101.SCH	XBRL Taxonomy Extension Schema Document			



**Table of Contents**

<b>Exhibit</b>			<b>SEC File or</b>	<b>Exhibit</b>
<b>Number</b>	<b>Document Description</b>	<b>Report or Registration Statement</b>	<b>Registration</b>	<b>or Other</b>
			<b>Number</b>	<b>Reference</b>
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document			
101.DEF	XBRL Taxonomy Definition Linkbase Document			
101.LAB	XBRL Taxonomy Extension Labels Linkbase Document			
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document			

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMEDISYS, INC.  
(Registrant)

By: /s/ Dale E. Redman

Dale E. Redman  
Chief Financial Officer and

Duly Authorized Officer

DATE: November 1, 2011

**Table of Contents****EXHIBIT INDEX**

The exhibits marked with the cross symbol ( ) are filed and the exhibits marked with the double cross symbol ( ) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (\*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

<b>Exhibit Number</b>	<b>Document Description</b>	<b>Report or Registration Statement</b>	<b>SEC File or Registration Number</b>	<b>Exhibit or Other Reference</b>
3.1	Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007	The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007	0-24260	3.1
3.2	Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009	The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009	0-24260	3.2
4.1	Common Stock Specimen	The Company's Registration Statement on Form S-3 filed August 20, 2007	333-145582	4.8
4.2	Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) \$35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) \$30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) \$35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.1
4.3	Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.2
4.4	Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.3
4.5	Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company's Current Report on Form 8-K filed on April 1, 2008	0-24260	4.4
31.1	Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002			
31.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002			
32.1	Certification of William F. Borne, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002			
32.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002			
101.INS	XBRL Instance			
101.SCH	XBRL Taxonomy Extension Schema Document			





**Table of Contents**

Exhibit	Number	Document Description	Report or Registration Statement	SEC File or Registration Number	Exhibit or Other Reference
	101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document			
	101.DEF	XBRL Taxonomy Definition Linkbase Document			
	101.LAB	XBRL Taxonomy Extension Labels Linkbase Document			
	101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document			